Drug profile · INN
telithromycin
KETEK
telithromycin (KETEK) is a bacterial 70s ribosome inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — telithromycin
- US status
- approved
- Class
- Antiinfectives for systemic use (J01)
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
telithromycin (KETEK) is a bacterial 70s ribosome inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial 70S ribosome inhibitor
Primary target: Bacterial 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is telithromycin?
telithromycin (KETEK) is a bacterial 70s ribosome inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for telithromycin?
KETEK is a marketed brand name for telithromycin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of telithromycin?
telithromycin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.